Subscribe

Chugai Pharmaceutical Co., Ltd. (4519.T)

JPY7,286.00 +56.00 (+0.77%)
JP JPX Healthcare Drug Manufacturers - General
Address Nihonbashi Mitsui Tower 103-8324
Tokyo, JP
CEO Osamu Okuda
Website chugai-pharm.co.jp
IPO 2000-01-04
ISIN JP3519400000

Explore sections of this company profile

Also trades on Other OTC · CHGCF (USD) Other OTC · CHGCY (USD) Tokyo Stock Exchange · 4519.T (JPY)
Description

Chugai Pharmaceutical Co., Ltd. is a prominent global pharmaceutical company, operating subsidiaries involved in the full lifecycle of drug development, from research and manufacturing to sales, import, and export, serving both Japanese and international markets. Its commercialized product portfolio spans several key therapeutic areas. These include a robust oncology offering with leading treatments like Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda. Additionally, it provides medications for bone health (e.g., Actemra, Edirol, Bonviva), renal conditions (such as Mircera and Oxarol), and neurological or other diverse ailments (including Hemlibra, CellCept, and Enspryng). Beyond its existing offerings, the company maintains an active research and development pipeline. This pipeline features multiple promising candidates targeting oncology, orthopedic and joint disorders, autoimmune diseases, kidney-related conditions, and various neurological or other health issues. Strategic partnerships are central to Chugai's operations, most notably a significant alliance with the Roche Group. The company also fosters collaborative research initiatives with academic institutions. Established in 1925, Chugai's headquarters are located in Tokyo, Japan, and it operates as a key subsidiary of Roche Holding Ltd.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
JPY7,286.00 +56.00 (+0.77%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
3M
Beta
0.55
Float Shares
639.89M
Free Float %
38.9%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+1.92% -1.51% -2.76% -24.51% -5.76% -7.33% +4.07% +106.87% +87.99% +503.98% +2,052.34%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
7,286.00
DCF (Unlevered) 6,073.24 -16.6%
DCF (Levered) 6,104.98 -16.2%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 60% Bullish
Rating 2026-05 Change
Strong Buy 4 0
Buy 5 0
Hold 6 0
Sell 0 0
Strong Sell 0 -1
Quality scores
Altman Z-Score
24.98
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
4 / 5
High
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Drug Manufacturers - General: +6.6%
    +7.5% ★ Q1'26: +11.5% (vs Q1'25)
  • ✓
    EPS growth Drug Manufacturers - General: +18.2%
    +12.1% Q1'26: +18.7% (vs Q1'25)
  • ✓
    FCF margin FCF growth · Drug Manufacturers - General: +36.0%
    +28.2% Q1'26: +34.4% (vs Q1'25)
  • ✓
    EBIT margin Drug Manufacturers - General: +19.4%
    +47.6% ★ Q1'26: +50.6% (vs Q1'25)
  • ✓
    ROIC Drug Manufacturers - General: +10.2%
    +41.6% ★ Q1'26: +43.6% (vs Q1'25)
  • ✗
    Share dilution Drug Manufacturers - General: +0.0%
    +0.0% Q1'26: 0.0% (vs Q1'25)
  • ✓
    Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - General: -0.29×
    0.00× ★ Q1'26: 0.03× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.56) × ERP
WACC = 100% × Ke + 0% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 6,073.24 Current price: 7,286.00
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
14 Rev. Ana.
15 EPS Ana. 		Dec 2027
14 Rev. Ana.
15 EPS Ana. 		Dec 2028
13 Rev. Ana.
14 EPS Ana. 		Dec 2029
12 Rev. Ana.
8 EPS Ana. 		Dec 2030
6 Rev. Ana.
12 EPS Ana.
Revenue
498.84B
est: 498.99B (0.0%)
491.78B
est: 491.80B (0.0%)
534.20B
est: 526.89B (+1.4%)
579.79B
est: 573.69B (+1.1%)
686.18B
est: 679.06B (+1.0%)
786.95B
est: 764.87B (+2.9%)
999.76B
est: 974.11B (+2.6%)
1.26T
est: 1.21T (+4.1%)
1.11T
est: 1.08T (+2.5%)
1.17T
est: 1.16T (+1.0%)
1.26T
est: 1.25T (+1.0%)
1.38T
1.35T – 1.44T
+11.0% YoY
1.53T
1.41T – 1.65T
+10.3% YoY
1.68T
1.68T – 1.68T
+9.9% YoY
1.86T
1.77T – 1.98T
+11.0% YoY
1.90T
1.80T – 2.02T
+2.1% YoY
EBITDA
102.92B
est: 222.92B (-53.8%)
90.90B
est: 219.71B (-58.6%)
113.43B
est: 235.38B (-51.8%)
138.08B
est: 256.29B (-46.1%)
234.41B
est: 303.36B (-22.7%)
328.72B
est: 341.70B (-3.8%)
450.30B
est: 435.18B (+3.5%)
562.66B
est: 540.55B (+4.1%)
475.64B
est: 615.04B (-22.7%)
574.80B
est: 657.54B (-12.6%)
631.37B
est: 706.46B (-10.6%)
784.04B
766.49B – 816.57B
+11.0% YoY
864.82B
799.95B – 938.52B
+10.3% YoY
950.44B
950.22B – 950.66B
+9.9% YoY
1.06T
1.00T – 1.12T
+11.0% YoY
1.08T
1.02T – 1.15T
+2.1% YoY
EBIT
87.35B
est: 207.93B (-58.0%)
74.53B
est: 204.94B (-63.6%)
97.09B
est: 219.56B (-55.8%)
121.51B
est: 239.06B (-49.2%)
208.01B
est: 282.97B (-26.5%)
298.25B
est: 318.73B (-6.4%)
419.43B
est: 405.92B (+3.3%)
531.23B
est: 504.21B (+5.4%)
443.90B
est: 590.76B (-24.9%)
543.13B
est: 631.57B (-14.0%)
598.83B
est: 678.56B (-11.7%)
753.08B
736.23B – 784.33B
+11.0% YoY
830.67B
768.36B – 901.46B
+10.3% YoY
912.91B
912.70B – 913.12B
+9.9% YoY
1.01T
962.79B – 1.08T
+11.0% YoY
1.03T
982.66B – 1.10T
+2.1% YoY
Net Income
61.13B
est: 61.36B (-0.4%)
53.59B
est: 53.03B (+1.1%)
72.71B
est: 72.98B (-0.4%)
92.49B
est: 91.22B (+1.4%)
157.56B
est: 160.11B (-1.6%)
214.73B
est: 215.23B (-0.2%)
303.00B
est: 292.67B (+3.5%)
374.43B
est: 359.02B (+4.3%)
325.47B
est: 355.04B (-8.3%)
387.32B
est: 395.44B (-2.1%)
434.01B
est: 452.20B (-4.0%)
510.64B
489.11B – 536.29B
+12.9% YoY
592.00B
500.48B – 668.60B
+15.9% YoY
674.58B
550.27B – 768.74B
+13.9% YoY
789.08B
737.77B – 855.20B
+17.0% YoY
853.31B
797.83B – 924.81B
+8.1% YoY
SGA
87.86B
est: 48.18B (+82.4%)
81.71B
est: 47.49B (+72.1%)
87.78B
est: 50.88B (+72.5%)
92.87B
est: 55.39B (+67.7%)
100.68B
est: 65.57B (+53.5%)
88.29B
est: 73.85B (+19.5%)
95.25B
est: 94.06B (+1.3%)
100.76B
est: 116.84B (-13.8%)
112.58B
est: 100.47B (+12.1%)
110.10B
est: 107.41B (+2.5%)
116.46B
est: 115.40B (+0.9%)
128.08B
125.21B – 133.39B
+11.0% YoY
141.27B
130.68B – 153.31B
+10.3% YoY
155.26B
155.22B – 155.29B
+9.9% YoY
172.36B
163.74B – 183.47B
+11.0% YoY
175.92B
167.12B – 187.26B
+2.1% YoY
EPS
37.33
est: 37.29 (+0.1%)
32.71
est: 32.23 (+1.5%)
44.35
est: 44.35 (+0.0%)
56.32
est: 55.43 (+1.6%)
95.95
est: 97.30 (-1.4%)
130.66
est: 130.79 (-0.1%)
184.29
est: 177.84 (+3.6%)
227.64
est: 218.16 (+4.3%)
197.83
est: 215.79 (-8.3%)
235.39
est: 237.49 (-0.9%)
263.73
est: 262.38 (+0.5%)
310.26
297.20 – 325.87
+18.2% YoY
358.49
304.11 – 406.26
+15.5% YoY
412.49
334.36 – 467.11
+15.1% YoY
479.47
448.30 – 519.65
+16.2% YoY
518.50
484.79 – 561.95
+8.1% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 A- 4/5 4/5 5/5 5/5 4/5 1/5 1/5
2026-05-28 A- 4/5 4/5 5/5 5/5 4/5 1/5 1/5
2026-05-27 A- 4/5 4/5 5/5 5/5 4/5 1/5 1/5
2026-05-26 A- 4/5 4/5 5/5 5/5 4/5 1/5 1/5
2026-05-25 A- 4/5 4/5 5/5 5/5 4/5 1/5 1/5
2026-05-22 A- 4/5 4/5 5/5 5/5 4/5 1/5 1/5
2026-05-21 A- 4/5 4/5 5/5 5/5 4/5 1/5 1/5
2026-05-20 A- 4/5 4/5 5/5 5/5 4/5 1/5 1/5
2026-05-19 A- 4/5 4/5 5/5 5/5 4/5 1/5 1/5
2026-05-18 A- 4/5 4/5 5/5 5/5 4/5 1/5 1/5
2026-05-15 A- 4/5 4/5 5/5 5/5 4/5 2/5 1/5
2026-05-14 A- 4/5 4/5 5/5 5/5 4/5 2/5 1/5
2026-05-13 A- 4/5 4/5 5/5 5/5 4/5 2/5 1/5
2026-05-12 A- 4/5 4/5 5/5 5/5 4/5 2/5 1/5
2026-05-11 A- 4/5 4/5 5/5 5/5 4/5 2/5 1/5
2026-05-08 B+ 3/5 3/5 5/5 5/5 3/5 2/5 1/5
2026-05-07 B+ 3/5 3/5 5/5 5/5 3/5 2/5 1/5
2026-05-01 B+ 3/5 3/5 5/5 5/5 3/5 2/5 1/5
2026-04-30 B+ 3/5 3/5 5/5 5/5 3/5 2/5 1/5
2026-04-28 A- 4/5 4/5 5/5 5/5 3/5 2/5 1/5
2026-04-27 A- 4/5 4/5 5/5 5/5 3/5 2/5 1/5
2026-04-24 B 3/5 3/5 5/5 5/5 1/5 2/5 1/5
2026-04-23 B 3/5 3/5 5/5 5/5 1/5 2/5 1/5
2026-04-22 B 3/5 3/5 5/5 5/5 1/5 2/5 1/5
2026-04-21 B+ 3/5 4/5 5/5 5/5 1/5 2/5 1/5
2026-04-20 B+ 3/5 4/5 5/5 5/5 1/5 2/5 1/5
2026-04-17 B+ 3/5 4/5 5/5 5/5 1/5 2/5 1/5
2026-04-16 B+ 3/5 4/5 5/5 5/5 1/5 2/5 1/5
2026-04-15 B+ 3/5 4/5 5/5 5/5 1/5 2/5 1/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
403.76B
OE per share TTM
245.34
Owner's Yield
3.11%
Maintenance CapEx ratio
0.52%
Maint CapEx / Avg PPE
36.3%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
119.15M
Shares Outstanding
1.65B

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Osamu Okuda President, Chief Executive Officer & Chairman 282M —
Junichi Takano Head of Marketing & Sales Division — —
Kaori Ouchi Executive Vice President — —
Kosuke Iijima Head of PHC Solution Department — male
Shinji Hidaka Executive Vice President — male
Tetsuya Yamaguchi Executive Vice President — male
Tomoyuki Igawa Vice President & Head of Research Division — —
Toshiya Sasai Executive of Investor Relations Group & Corporation Communications Department — —
Iwaaki Taniguchi Senior Executive Officer, CFO, Head of Finance & Director — male
Yoshiyuki Yano Executive Vice President — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Drug Manufacturers - General